search

Active clinical trials for "Schizophrenia"

Results 2291-2300 of 3086

Improving Outcomes for Individuals With Serious Mental Illness and Diabetes

Diabetes MellitusBipolar Disorder3 more

This project tests a model for improving illness self-management among persons who have both serious mental illness and diabetes and will be performed within a primary care setting at a safety net hospital system. The information gained from the randomized trial will be supplemented with reports from participants about their experiences of trying to improve illness self-management. Improvements in self-management should result in a reduction of psychiatric symptoms and improvements in functioning and physical health.

Completed10 enrollment criteria

Effect of Calories and Fat Content on the Pharmacokinetics of Lurasidone HCl

SchizophreniaSchizoaffective Disorder1 more

The objective of this study is to evaluate the effect of calorie and fat content on the pharmacokinetics of Lurasidone HCl in subjects with schizophrenia, schizoaffective disorder, or schizophreniform disorder.

Completed6 enrollment criteria

Effects of Delta-9-THC and Iomazenil in Healthy Humans

SchizophreniaMental Disorders1 more

The study aims to examine the combined effects of delta-9-tetrahydrocannabinol (∆-9-THC or THC) and iomazenil on thinking, perception, mood, memory, attention, and electrical activity of the brain (EEG). THC is the active ingredient of marijuana, cannabis, "ganja", or "pot". Iomazenil is a drug that works opposite to drugs like valium. The purpose of this study is to determine whether the administration of iomazenil will alter the effects of THC.

Completed3 enrollment criteria

Outcome Evaluation of Solutions for Wellness and Team Solutions Program in Patients With Severe...

SchizophreniaSchizoaffective Disorder1 more

Obesity is increasing at an alarming rate in patients with schizophrenia, possibly in association with the increased use of atypical antipsychotics. In order to address the weight and metabolic syndrome issues, Manhattan Psychiatric Center (MPC) has implemented the Solutions for Wellness and Team Solutions Program. This program is designed to create a supportive, educational and monitoring environment to stabilize both the psychiatric and medical conditions and to prepare patients for independent management of their psychiatric and physical health condition in the community.

Completed8 enrollment criteria

Demonstrate the Effects of Pramlintide on Weight Reduction in Schizophrenia

SchizophreniaSchizoaffective Disorder2 more

Primary Objective: To test the effect of pramlintide on body weight in clozapine- and olanzapine-induced weight gain in persons with schizophrenia who are currently taking either drug; measures of the metabolic syndrome will be evaluated as well.

Completed18 enrollment criteria

Training-induced Cerebral Reorganization in Schizophrenia

Schizophrenia

The purpose of this study is to reveal the effects of computer-aided cognitive-auditory training on cerebral reorganization in schizophrenia.

Completed5 enrollment criteria

Study Comparing Bioavailability of Oral Formulations of Vabicaserin

Schizophrenia

The purpose of this study is to determine the absorption rate of four oral formulations of vabicaserin.

Completed4 enrollment criteria

Escitalopram in Schizophrenia in OCD- Open Label Study

Schizophrenia

SSRI's has been demonstrated to be partially effective in schizophrenia and OCD. We therefore suggest that Escitalopram up to 20 mg /d in those patients could be effective in reducing obsessive compulsive symptomatology

Completed4 enrollment criteria

Rehabilitative Training for Older People With Schizophrenia

Schizophrenia

This study will evaluate the effectiveness of a rehabilitation program called Functional Adaptation Skills Training (FAST) in treating older patients with schizophrenia.

Completed1 enrollment criteria

Augmenting Zyprexa With Naltrexone to Ameliorate Metabolic Side-Effects

SchizophreniaPsychotic Disorders

The main purpose of this study is to determine whether the opioid antagonist naltrexone is helpful in ameliorating the weight gain and other adverse metabolic side effects experienced by schizophrenic patients taking the second generation antipsychotic (SGA) Zyprexa. Schizophrenics may have an altered/enhanced endogenous opioidergic drive, and because of this, normally painful stimuli will be sensed as less painful in schizophrenics vs. healthy controls. A secondary hypothesis for this study is that naltrexone augmentation of Zyprexa will normalize subjective pain ratings. Our tertiary objective is to examine the safety and tolerability of naltrexone in Zyprexa-treated patients with schizophrenia.

Completed20 enrollment criteria
1...229230231...309

Need Help? Contact our team!


We'll reach out to this number within 24 hrs